1. Home
  2. VGAS vs MRKR Comparison

VGAS vs MRKR Comparison

Compare VGAS & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Verde Clean Fuels Inc.

VGAS

Verde Clean Fuels Inc.

HOLD

Current Price

$1.16

Market Cap

23.8M

Sector

Industrials

ML Signal

HOLD

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$1.22

Market Cap

22.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VGAS
MRKR
Founded
2007
1999
Country
United States
United States
Employees
12
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.8M
22.5M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
VGAS
MRKR
Price
$1.16
$1.22
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
22.7K
62.4K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.61
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$936.27
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.92
$0.81
52 Week High
$3.36
$2.46

Technical Indicators

Market Signals
Indicator
VGAS
MRKR
Relative Strength Index (RSI) 51.56 33.81
Support Level $0.95 $1.17
Resistance Level $2.01 $1.52
Average True Range (ATR) 0.09 0.07
MACD 0.02 -0.03
Stochastic Oscillator 89.66 1.76

Price Performance

Historical Comparison
VGAS
MRKR

About VGAS Verde Clean Fuels Inc.

Verde Clean Fuels Inc is a renewable energy company specializing in the conversion of synthesis gas, or syngas, derived from diverse feedstocks, such as biomass, MSW, and mixed plastics, as well as natural gas (including synthetic natural gas) and other feedstocks, into liquid hydrocarbons that can be used as gasoline through a proprietary liquid fuels technology, the STG process.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).

Share on Social Networks: